{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:49:16Z","timestamp":1780073356885,"version":"3.54.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["-02576-18"],"award-info":[{"award-number":["-02576-18"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["CAPES-COFECUB 768\/13"],"award-info":[{"award-number":["CAPES-COFECUB 768\/13"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["-02864-16"],"award-info":[{"award-number":["-02864-16"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["7\\u201314"],"award-info":[{"award-number":["7\\u201314"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["442351\/2017-8"],"award-info":[{"award-number":["442351\/2017-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["313602\/2019-0"],"award-info":[{"award-number":["313602\/2019-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Parasitology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.exppara.2021.108142","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T03:52:13Z","timestamp":1628394733000},"page":"108142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease"],"prefix":"10.1016","volume":"228","author":[{"given":"Pollyanna \u00c1lvaro","family":"Sp\u00f3sito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1642-306X","authenticated-orcid":false,"given":"Ana Lia","family":"Mazzeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly Christyne Miranda Pereira","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila Fagundes","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-0378","authenticated-orcid":false,"given":"Julio A.","family":"Urbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Terezinha","family":"Bahia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-6090","authenticated-orcid":false,"given":"Vanessa Carla Furtado","family":"Mosqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exppara.2021.108142_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3109\/03639045.2014.886695","article-title":"Formulation of solid self-nanoemulsifying drug delivery systems using N -methyl pyrrolidone as cosolvent","volume":"41","author":"Agrawal","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.exppara.2021.108142_bib2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s11095-010-0309-1","article-title":"Nano-emulsions and micro-emulsions: clarifications of the critical differences","volume":"28","author":"Anton","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.exppara.2021.108142_bib3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/13543784.2014.922952","article-title":"Therapeutical approaches under investigation for treatment of Chagas disease","volume":"23","author":"Bahia","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.exppara.2021.108142_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1590\/S1806-83242009000300006","article-title":"A simple method to measure cell viability in proliferation and cytotoxicity assays","volume":"23","author":"Borra","year":"2009","journal-title":"Braz. Oral Res."},{"key":"10.1016\/j.exppara.2021.108142_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01937-19","article-title":"Lychnopholide in poly(D,L-Lactide)- block -polyethylene glycol nanocapsules cures infection with a drug-resistant Trypanosoma cruzi strain at acute and chronic phases","volume":"64","author":"Branquinho","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2021.108142_bib6","first-page":"389","article-title":"Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi","volume":"4","author":"Brener","year":"1962","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.exppara.2021.108142_bib7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.exppara.2021.108142_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.exppara.2007.08.016","article-title":"Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole","volume":"118","author":"Caldas","year":"2008","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.exppara.2021.108142_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2004.03.001","article-title":"Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo","volume":"278","author":"Cornaire","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.exppara.2021.108142_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0166-6851(03)00093-8","article-title":"Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR","volume":"129","author":"Cummings","year":"2003","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.exppara.2021.108142_bib11","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/nnm.10.126","article-title":"Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances","volume":"5","author":"Date","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.exppara.2021.108142_bib12","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1128\/AAC.00178-16","article-title":"Efficacy of lychnopholide polymeric nanocapsules after oral and intravenous administration in murine experimental Chagas disease","volume":"60","author":"de Mello","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2021.108142_bib13","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.01742-09","article-title":"Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with trypanosoma cruzi. Antimicrob","volume":"54","author":"Diniz","year":"2010","journal-title":"Agents Chemother"},{"key":"10.1016\/j.exppara.2021.108142_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00401-18","article-title":"Outcome of E1224-benznidazole combination treatment for infection with a multidrug-resistant Trypanosoma cruzi strain in mice","volume":"62","author":"Diniz","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2021.108142_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/10611860290022688","article-title":"Absorption enhancing effect of Labrasol on the intestinal absorption of insulin in rats","volume":"10","author":"Eaimtrakarn","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.exppara.2021.108142_bib16","series-title":"Noxafil","year":"2018"},{"key":"10.1016\/j.exppara.2021.108142_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpddr.2020.06.001","article-title":"Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity","volume":"13","author":"Franco","year":"2020","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.exppara.2021.108142_bib18","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1128\/AAC.48.11.4286-4292.2004","article-title":"Activity of the new triazole derivative albaconazole against trypanosoma (schizotrypanum) cruzi in dog hosts","volume":"48","author":"Guedes","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2021.108142_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1021\/js970300n","article-title":"Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor","volume":"87","author":"Hauss","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.exppara.2021.108142_bib20","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/S0024-3205(01)01375-3","article-title":"A novel emulsifier, Labrasol, enhances gastrointestinal absorption of gentamicin","volume":"69","author":"Hu","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.exppara.2021.108142_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1211\/jpp.61.03.0004","article-title":"Galactose-grafted chylomicron-mimicking emulsion: evaluation of specificity against HepG-2 and MCF-7 cell lines","volume":"61","author":"Jain","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.exppara.2021.108142_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0939-6411(02)00116-9","article-title":"In vitro and in situ evidence for the contribution of Labrasol\u00ae and Gelucire 44\/14 on transport of cephalexin and cefoperazone by rat intestine","volume":"54","author":"Koga","year":"2002","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.exppara.2021.108142_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jps.20767","article-title":"Development and validation of a preclinical food effect model","volume":"96","author":"Lentz","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.exppara.2021.108142_bib24","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1017\/S0031182018000562","article-title":"CYP51 as drug targets for fungi and protozoan parasites: past, present and future","volume":"145","author":"Lepesheva","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.exppara.2021.108142_bib25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1248\/bpb.30.1301","article-title":"Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of Rhodamine123, a P-glycoprotein substrate, in rats","volume":"30","author":"Lin","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.exppara.2021.108142_bib26","doi-asserted-by":"crossref","first-page":"105234","DOI":"10.1016\/j.ejps.2020.105234","article-title":"Benznidazole self-emulsifying delivery system: a novel alternative dosage form for Chagas disease treatment","volume":"145","author":"Mazzeti","year":"2020","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.exppara.2021.108142_bib27","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas' disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exppara.2021.108142_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jac\/46.1.137","article-title":"In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi","volume":"46","author":"Molina","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2021.108142_bib29","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development","volume":"4","author":"Moraes","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exppara.2021.108142_bib30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic Chagas' cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exppara.2021.108142_bib31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/j.2042-7158.2010.01107.x","article-title":"New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs: lipid and surfactant drug delivery systems","volume":"62","author":"M\u00fcllertz","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.exppara.2021.108142_bib32","article-title":"In vitro and in vivo studies of the trypanocidal effect of novel quinolines","volume":"62","author":"Nefertiti","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2021.108142_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","article-title":"Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs","volume":"58","author":"Neslihan Gursoy","year":"2004","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.exppara.2021.108142_bib34","first-page":"405","article-title":"Lipid-based formulations for intestinal lymphatic delivery","volume":"15","author":"O'Driscoll","year":"2002","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.exppara.2021.108142_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.addr.2007.10.014","article-title":"Enhancing intestinal drug solubilisation using lipid-based delivery systems","volume":"60","author":"Porter","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.exppara.2021.108142_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.addr.2007.10.010","article-title":"Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies","volume":"60","author":"Pouton","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.exppara.2021.108142_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0378-5173(02)00544-6","article-title":"Enhanced intestinal absorption of vancomycin with Labrasol and d-\u03b1-tocopheryl PEG 1000 succinate in rats","volume":"250","author":"Prasad","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.exppara.2021.108142_bib38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0022-2275(20)32514-1","article-title":"Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture","volume":"39","author":"Rinninger","year":"1998","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.exppara.2021.108142_bib39","series-title":"Assay Guidance Manual","article-title":"Cell viability assays","author":"Riss","year":"2004"},{"key":"10.1016\/j.exppara.2021.108142_bib40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1211\/0022357056118","article-title":"Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs","volume":"57","author":"Sakaeda","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.exppara.2021.108142_bib41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejps.2005.01.001","article-title":"Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells","volume":"24","author":"Sha","year":"2005","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.exppara.2021.108142_bib42","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.2147\/IJN.S133708","article-title":"Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity","volume":"12","author":"Sp\u00f3sito","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.exppara.2021.108142_bib43","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ejmech.2017.08.055","article-title":"Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi","volume":"139","author":"Tempone","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.exppara.2021.108142_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.exppara.2021.108142_bib45","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1016\/j.bmcl.2003.08.029","article-title":"Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties","volume":"13","author":"Ueda","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.exppara.2021.108142_bib46","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ejps.2012.07.005","article-title":"Evaluation of cytotoxicity of surfactants used in self-micro emulsifying drug delivery systems and their effects on paracellular transport in Caco-2 cell monolayer","volume":"47","author":"Ujhelyi","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.exppara.2021.108142_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jacc.2017.03.611","article-title":"Pharmacodynamics and follow-up period in the treatment of human trypanosoma cruzi infections with posaconazole","volume":"70","author":"Urbina","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.exppara.2021.108142_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jeu.12184","article-title":"Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives","volume":"62","author":"Urbina","year":"2015","journal-title":"J. Eukaryot. Microbiol."},{"key":"10.1016\/j.exppara.2021.108142_bib49","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/AAC.42.7.1771","article-title":"Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies","volume":"42","author":"Urbina","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2021.108142_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0924-8579(02)00273-X","article-title":"In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease","volume":"21","author":"Urbina","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.exppara.2021.108142_bib51","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/infdis\/jit042","article-title":"VNI cures acute and chronic experimental Chagas disease","volume":"208","author":"Villalta","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.exppara.2021.108142_bib52","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/17460441.2019.1652593","article-title":"Advances in preclinical approaches to Chagas disease drug discovery","volume":"14","author":"Villalta","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.exppara.2021.108142_bib53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2021.108142_bib54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcis.2008.10.077","article-title":"Design and optimization of a new self-nanoemulsifying drug delivery system","volume":"330","author":"Wang","year":"2009","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.exppara.2021.108142_bib55","author":"WHO"}],"container-title":["Experimental Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489421000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489421000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:26:17Z","timestamp":1778657177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014489421000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":55,"alternative-id":["S0014489421000795"],"URL":"https:\/\/doi.org\/10.1016\/j.exppara.2021.108142","relation":{},"ISSN":["0014-4894"],"issn-type":[{"value":"0014-4894","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exppara.2021.108142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108142"}}